evolving landscape of lung cancer treatmentgrupogallegocancerdepulmon.org/xx_reunion_anual/21... ·...
Post on 26-Jul-2020
2 Views
Preview:
TRANSCRIPT
Evolving landscape of lung cancer treatment
Figure adapted from Pao, et al. Lancet Oncol 2011
ChemotherapyChemotherapy
± anti-angiogenicsTargeted therapy Cancer immunotherapy
Histological subtype
Molecular pathology (EGFR / ALK / ROS1 / BRAF)
Checkpoint inhibition
NSCLC vs SCLC
1980s 2000s 2015+
Situación en el 2016 del CPNCP estadio IV
ROS1 mutation
Los inicios…
EGFR
Formato taller
Mechanisms of EGFR resistance
ALK
Un año más….
Sequence EGFR mut patients?
EGFR TKI 1st G8-13,7 m
50% T790M=Osimertinib9,6 m
CT 1L=6 mCT 2=3,4 m
CT 1L=6 mCT 2=3,4 m
50% T790M=Osimertinib9,6 m
EGFR TKI 2nd G11-16,6 m
Erlotinib + Bevacizumab16 m
Resistance? OS data?
Osimertinib19 m
Resistance?OS data?
Volvemos a una tarde
Id reservando lugar en la agenda…
top related